These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 26222760

  • 61. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
    Wu Y, Liu FF, Xu Y, Wang JJ, Samadli S, Wu YF, Liu HH, Chen WX, Luo HH, Zhang DD, Wei W, Hu P.
    Clin Exp Med; 2019 May; 19(2):173-181. PubMed ID: 30617865
    [Abstract] [Full Text] [Related]

  • 62. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
    Chen S, Dong Y, Kiuchi MG, Wang J, Li R, Ling Z, Zhou T, Wang Z, Martinek M, Pürerfellner H, Liu S, Krucoff MW.
    JAMA Pediatr; 2016 Dec 01; 170(12):1156-1163. PubMed ID: 27749951
    [Abstract] [Full Text] [Related]

  • 63. Effect of i.v. immunoglobulin in the first 4 days of illness in Kawasaki disease.
    Shiozawa Y, Inuzuka R, Shindo T, Mafune R, Hayashi T, Hirata Y, Shimizu N, Inatomi J, Yokoyama Y, Namai Y, Oda Y, Takamizawa M, Harita Y, Kawahara T, Oka A.
    Pediatr Int; 2018 Apr 01; 60(4):334-341. PubMed ID: 29292568
    [Abstract] [Full Text] [Related]

  • 64. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases.
    Li X, Chen Y, Tang Y, Ding Y, Xu Q, Sun L, Qian W, Qian G, Qin L, Lv H.
    Eur J Pediatr; 2018 Aug 01; 177(8):1279-1292. PubMed ID: 29948255
    [Abstract] [Full Text] [Related]

  • 65. [Risk factors for coronary artery lesions in children with Kawasaki disease].
    Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec 01; 14(12):938-41. PubMed ID: 23234782
    [Abstract] [Full Text] [Related]

  • 66. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
    Lancet Child Adolesc Health; 2021 Dec 01; 5(12):852-861. PubMed ID: 34715057
    [Abstract] [Full Text] [Related]

  • 67. The effects of glucocorticoid plus intravenous immunoglobulin (IVIG) vs IVIG alone on platelet activation in children with Kawasaki disease.
    Wang QQ, Zheng LY, Zhao S.
    Turk J Pediatr; 2023 Dec 01; 65(4):640-649. PubMed ID: 37661679
    [Abstract] [Full Text] [Related]

  • 68. [Values of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in predicting sensitivity to intravenous immunoglobulin in Kawasaki disease].
    Yuan YD, Sun J, Li PF, Wei CL, Yu YH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2017 Apr 01; 19(4):410-413. PubMed ID: 28407827
    [Abstract] [Full Text] [Related]

  • 69. Predicting IVIG resistance in UK Kawasaki disease.
    Davies S, Sutton N, Blackstock S, Gormley S, Hoggart CJ, Levin M, Herberg JA.
    Arch Dis Child; 2015 Apr 01; 100(4):366-8. PubMed ID: 25670405
    [Abstract] [Full Text] [Related]

  • 70. Prediction of intravenous immunoglobulin resistance in Kawasaki disease in children.
    Wu S, Liao Y, Sun Y, Zhang CY, Zhang QY, Yan H, Qi JG, Liu XQ, Chen YH, Wang YL, Li XY, Jin HF, Du JB.
    World J Pediatr; 2020 Dec 01; 16(6):607-613. PubMed ID: 32232677
    [Abstract] [Full Text] [Related]

  • 71. Coronary artery status of patients with transient fever 24-36 h after first IVIG infusion did not differ from that seen in responsive patients.
    Baek JS, Yu JJ, Kim MJ, You J, Jun HO, Kim YH, Ko JK.
    Pediatr Rheumatol Online J; 2018 Dec 29; 16(1):83. PubMed ID: 30594188
    [Abstract] [Full Text] [Related]

  • 72. Effectiveness of two same-manufacturer intravenous immunoglobulin for Kawasaki disease.
    Wu KL, Lin MT, Chang YJ.
    J Formos Med Assoc; 2024 Apr 29; 123(4):517-522. PubMed ID: 38097428
    [Abstract] [Full Text] [Related]

  • 73. Risk factors for failure of initial intravenous immunoglobulin treatment in Kawasaki disease.
    Cha S, Yoon M, Ahn Y, Han M, Yoon KL.
    J Korean Med Sci; 2008 Aug 29; 23(4):718-22. PubMed ID: 18756064
    [Abstract] [Full Text] [Related]

  • 74. Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease.
    Kitoh T, Ohara T, Muto T, Okumura A, Baba R, Koizumi Y, Yamagishi Y, Mikamo H, Daigo K, Hamakubo T.
    Front Immunol; 2021 Aug 29; 12():624802. PubMed ID: 33912155
    [Abstract] [Full Text] [Related]

  • 75. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb 29; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 76. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov 29; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 77. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
    Xie T, Wang Y, Fu S, Wang W, Xie C, Zhang Y, Gong F.
    Pediatr Rheumatol Online J; 2017 Mar 21; 15(1):17. PubMed ID: 28320400
    [Abstract] [Full Text] [Related]

  • 78. Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance.
    Tajima M, Shiozawa Y, Kagawa J.
    Pediatr Cardiol; 2015 Aug 21; 36(6):1159-65. PubMed ID: 25753685
    [Abstract] [Full Text] [Related]

  • 79. A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease.
    Takeshita S, Kanai T, Kawamura Y, Yoshida Y, Nonoyama S.
    PLoS One; 2017 Aug 21; 12(5):e0176957. PubMed ID: 28542183
    [Abstract] [Full Text] [Related]

  • 80. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand.
    Durongpisitkul K, Sangtawesin C, Khongphatthanayopthin A, Panamonta M, Sopontammarak S, Sittiwangkul R, Pongpanich B.
    Asian Pac J Allergy Immunol; 2006 Mar 21; 24(1):27-32. PubMed ID: 16913186
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.